Review
BibTex RIS Cite

The Utilization Areas of Cabergoline in Veterinary Gynecology

Year 2019, , 77 - 81, 18.07.2019
https://doi.org/10.30782/uluvfd.418900

Abstract

Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary
gland. It reduces the amount of plasma prolactin and inhibits progesterone secretion at the same time. Because of these effects, it has found a
widespread area of use in the treatment of hyperprolactinemic disorders both in the human medicine and veterinary medicine.

References

  • 1- Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Int J Clin Endocrinol Metab. 1997; 82(3): 876-883.
  • 2- Kaya S. Üremeyi Etkileyen Hormonlar In: Kaya S, ed. Veteriner Farmakoloji 4. Baskı Ankara Medisan Yayınevi 2007:81
  • 3- Balçık O, 2007. Hiperprolaktinomide kabergolinin düşük doz ve kısa dönem idame tedavisinin etkinliğinin araştırılması. T.C. Saglık Bakanlıgı Dr. Lütfi Kırdar Kartal Egitim ve Arastırma Hastanesi 2. Kadın Hastalıkları ve Dogum Klinigi Uzmanlık Tezi
  • 4- Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Int J Clin Endocrinol Metab. 2000; 85(6):2247-2252.
  • 5- Jochle W, Arbeiter K, Post K, Ballabio R. Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J Reprod Fertil. 1989; 39:199-207
  • 6- Verstegen JP, Onclin K, Silva LD, et al. Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline. J Reprod Fertil. 1993; ( 47): 411-417.
  • 7- Eguchi K, Kawamoto K, Uozumi T, et al. Effect of Cabergoline, a Dopamine Agonist, on Estrogen-Induced Rat Pituitary Tumors. Endocr J. 1995; 42(3): 413-420.
  • 8- Concannon PW. Reproductive cycles of the domestic bitch. Anim Reprod Sci. 2011; 124(3): 200-210.
  • 9- Nak D, Nak Y, Simsek G. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches. Aust Vet J. 2012; 90(5): 194- 196.
  • 10- Kalkan C, Horoz H, 2001. Pubertas ve Seksüel Sikluslar In: Alaçam E, ed. Evcil Hayvanlarda Doğum ve İnfertilite 3. Baskı Ankara Medisan Yayınevi 2001: 23-40 11- Rains CP, Bryson HM, Fitton A. Cabergoline. Drugs. 1995; 49(2): 255-279.
  • 12- Günay A, 2015. Köpeklerde Östrus Siklusunu Uyarma Yöntemleri. Acta Vet Eurasia. 2015; 41(2): 238-244. 13- Kutzler MA. Estrus induction and synchronization in canids and felids. Theriogenology. 2007; 68(3):354- 374.
  • 14- Gobello C, Castex G, Corrada Y. Use of cabergoline to treat primary and secondary anestrus in dogs. JAVMA. 2002; 220(11): 1653-1654.
  • 15- Verstegen JP, Onclin K, Silva LDM, et al. Effect of stage of anestrus on the induction of estrus by the dopamine agonist cabergoline in dogs. Theriogenology. 1999; 51(3): 597-611.
  • 16- Rota A, Mollo A, Marinelli L, et al. Evaluation of cabergoline and buserelin efficacy for oestrous induction in the bitch. Reprod Domest Anim. 2003; 38(6): 440-443.
  • 17- Cirit U, Bacınoglu, S, Tas M, et al. Use of a decreased dose of cabergoline to treat secondary anoestrus in bitches. Bull Vet Inst Pulawy. 2007; 51(1):43-46.
  • 18- Gobello C. Dopamine agonists, anti-progestins, anti- androgens, long-term-release GnRH agonists and anti-estrogens in canine reproduction. Theriogenology. 2006; 66(6): 1560-1567.
  • 19- Wanke MM, Romagnoli S, Verstegen J, Concannon PW. Pharmacological approaches to pregnancy termination in dogs and cats including the use of prostaglandins, dopamine agonists, and dexamethasone In: Concannon PW, England G, Verstegen J and C. Linde-Forsberg , ed.Recent Advances in Small Animal Reproduction, Publisher: International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA.. This document is available on-line at www.ivis. org. 2002; Document No. A1223.0802.
  • 20- Post K, Evans LE, Jöchle W. Effects of prolactin suppression with cabergoline on the pregnancy of the bitch. Theriogenology. 1998; 29(6): 1233-1243.
  • 21- Onclin K, Silva LD, Donnay I, et al. Luteotrophic action of prolactin in dogs and the effects of a dopamine agonist, cabergoline. J Reprod Infertil. 1992; (47):403-409.
  • 22- Arbeiter K, Flatscher C. Induction of abortion in the bitch using cabergoline (Galastop). Kleintierpraxis. 1996; 41: 747.
  • 23- Eilts BE. Pregnancy termination in the bitch and queen. Top Companion Anim Med. 2002; 17(3): 116- 123.
  • 24- Wiebe, VJ, Howard, JP. Pharmacologic advances in canine and feline reproduction. Top Companion Anim Med. 2009; 24(2): 71-99.
  • 25- Erünal-Maral N, Aslan S, Fındık M, et al. Alfaprostol (Gabbrostim™) induction of abortion in queens by administration of cabergoline (Galastop™) solely or in combination with the PGF2α analogue. Theriogenology. 2004; 61(7): 1471-1475.
  • 26- Hollinshead F, Krekeler N. Pyometra in the queen: To spay or not to spay? J Feline Med Surg. 2016; 18(1): 21-33.
  • 27- England GCW, Freeman SL, Russo M. Treatment of spontaneous pyometra in 22 bitches with a combination of cabergoline and cloprostenol. Vet Rec. 2007; 160: 293-296.
  • 28- Jena B, Rao KS, Reddy KCS, et al. Comparative efficacy of various therapeutic protocols in the treatment of pyometra in bitches. Vet Med. 2013; 58(5): 271-276.
  • 29- Gobello C, De La Sota RL, Goya RG. A review of canine pseudocyesis. Reprod Domest Anim. 2001; 36(6): 283-288.
  • 30- Tsutsui T, Kirihara N, Hori T, et al. Plasma progesterone and prolactin concentrations in overtly pseudopregnant bitches: a clinical study. Theriogenology. 2007; 67(5): 1032-1038.
  • 31- Mir F, Fontfaonne A. Management of pseudopregnancy lactation refractory to medical treatment in bitches Point Veterinaire. 2013; 44(334): 6-9.
  • 32- Giesenberg S. Pseudopregnancy in the bitch. Aust Vet P. 2004; 34(4): 164-168.
  • 33- Harvey MJA, Cauvin A, Dale M, et al. Effect and mechanisms of the antiprolactin drug cabergoline on pseudopregnancy in the bitch. J Small Anim Pract. 1997; 38(8):36-339.
  • 34- Baştan A, Fındık M, Erunal N, et al. The use of cabergoline for treatment of pseudopregnancy in dogs with the purpose of suppressing lactation. Reprod Domest Anim. 1998; 33(2): 49-53.
  • 35- Sathiamoorthy T, Kulasekar K, Joseph C, et al. Clinical management of pseudopregnancy in bitches with cabergoline. Indian Vet J. 2007; 84(2): 184- 185.
  • 36- Dvojkovic N, Macesic N, Bacic G, et al. Feline fibroepithelial hyperplasia (FEH) treatment options. Kleintierpraxis. 2015; 60(5): 237-243.
  • 37- Wehrend A, Hospes R, Gruber AD. Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Vet Rec. 2001; 148(11): 346.
  • 38- MacDougalL LD. Mammary fibroadenomatous hyperplasia in a young cat attributed to treatment with megestrol acetate. Can Vet J. 2003; 44(3): 227-229.
  • 39- Concannon PW, Verstegen J. Some unique aspects of canine and feline female reproduction important in veterinary practice. In Proc.: 3rd World Congress of the World Small Anim. Vet. Assoc. 11-14 May 2005. Mexico City, Mexico.
  • 40- Uçmak M, Enginler SÖ, Gündüz MC, et al. Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline. Acta Vet Eurasia. 2011; 37(1): 69-74.
  • 41- Boutinaud M, Isaka N., Lollivier V, et al. Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off. J Dairy Sci. 2016; 99(7): 5707-5718.
  • 42- Özyurtlu N, Doğruer G, 2016. Memenin Fizyolojisi In: Kaymaz M. , Fındık M. , Rişvanlı A. , Köker A, ed.Evcil Hayvanlarda Meme Hastalıkları 1. Baskı Malatya Medipres Matbaacılık Yayıncılık Ltd. Şti. 2016: 23-35.
  • 43- Bach A, De-Prado A, Aris A. The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior. J Dairy Sci. 2015; 98(10): 7097-7101.
  • 44- Bertulat S, Isaka N, de Prado A, et al. Effect of a single injection of cabergoline at dry off on udder characteristics in high-yielding dairy cows. J Dairy Sci. 2017; 100(4): 3220-3232.
Year 2019, , 77 - 81, 18.07.2019
https://doi.org/10.30782/uluvfd.418900

Abstract

References

  • 1- Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Int J Clin Endocrinol Metab. 1997; 82(3): 876-883.
  • 2- Kaya S. Üremeyi Etkileyen Hormonlar In: Kaya S, ed. Veteriner Farmakoloji 4. Baskı Ankara Medisan Yayınevi 2007:81
  • 3- Balçık O, 2007. Hiperprolaktinomide kabergolinin düşük doz ve kısa dönem idame tedavisinin etkinliğinin araştırılması. T.C. Saglık Bakanlıgı Dr. Lütfi Kırdar Kartal Egitim ve Arastırma Hastanesi 2. Kadın Hastalıkları ve Dogum Klinigi Uzmanlık Tezi
  • 4- Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Int J Clin Endocrinol Metab. 2000; 85(6):2247-2252.
  • 5- Jochle W, Arbeiter K, Post K, Ballabio R. Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J Reprod Fertil. 1989; 39:199-207
  • 6- Verstegen JP, Onclin K, Silva LD, et al. Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline. J Reprod Fertil. 1993; ( 47): 411-417.
  • 7- Eguchi K, Kawamoto K, Uozumi T, et al. Effect of Cabergoline, a Dopamine Agonist, on Estrogen-Induced Rat Pituitary Tumors. Endocr J. 1995; 42(3): 413-420.
  • 8- Concannon PW. Reproductive cycles of the domestic bitch. Anim Reprod Sci. 2011; 124(3): 200-210.
  • 9- Nak D, Nak Y, Simsek G. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches. Aust Vet J. 2012; 90(5): 194- 196.
  • 10- Kalkan C, Horoz H, 2001. Pubertas ve Seksüel Sikluslar In: Alaçam E, ed. Evcil Hayvanlarda Doğum ve İnfertilite 3. Baskı Ankara Medisan Yayınevi 2001: 23-40 11- Rains CP, Bryson HM, Fitton A. Cabergoline. Drugs. 1995; 49(2): 255-279.
  • 12- Günay A, 2015. Köpeklerde Östrus Siklusunu Uyarma Yöntemleri. Acta Vet Eurasia. 2015; 41(2): 238-244. 13- Kutzler MA. Estrus induction and synchronization in canids and felids. Theriogenology. 2007; 68(3):354- 374.
  • 14- Gobello C, Castex G, Corrada Y. Use of cabergoline to treat primary and secondary anestrus in dogs. JAVMA. 2002; 220(11): 1653-1654.
  • 15- Verstegen JP, Onclin K, Silva LDM, et al. Effect of stage of anestrus on the induction of estrus by the dopamine agonist cabergoline in dogs. Theriogenology. 1999; 51(3): 597-611.
  • 16- Rota A, Mollo A, Marinelli L, et al. Evaluation of cabergoline and buserelin efficacy for oestrous induction in the bitch. Reprod Domest Anim. 2003; 38(6): 440-443.
  • 17- Cirit U, Bacınoglu, S, Tas M, et al. Use of a decreased dose of cabergoline to treat secondary anoestrus in bitches. Bull Vet Inst Pulawy. 2007; 51(1):43-46.
  • 18- Gobello C. Dopamine agonists, anti-progestins, anti- androgens, long-term-release GnRH agonists and anti-estrogens in canine reproduction. Theriogenology. 2006; 66(6): 1560-1567.
  • 19- Wanke MM, Romagnoli S, Verstegen J, Concannon PW. Pharmacological approaches to pregnancy termination in dogs and cats including the use of prostaglandins, dopamine agonists, and dexamethasone In: Concannon PW, England G, Verstegen J and C. Linde-Forsberg , ed.Recent Advances in Small Animal Reproduction, Publisher: International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA.. This document is available on-line at www.ivis. org. 2002; Document No. A1223.0802.
  • 20- Post K, Evans LE, Jöchle W. Effects of prolactin suppression with cabergoline on the pregnancy of the bitch. Theriogenology. 1998; 29(6): 1233-1243.
  • 21- Onclin K, Silva LD, Donnay I, et al. Luteotrophic action of prolactin in dogs and the effects of a dopamine agonist, cabergoline. J Reprod Infertil. 1992; (47):403-409.
  • 22- Arbeiter K, Flatscher C. Induction of abortion in the bitch using cabergoline (Galastop). Kleintierpraxis. 1996; 41: 747.
  • 23- Eilts BE. Pregnancy termination in the bitch and queen. Top Companion Anim Med. 2002; 17(3): 116- 123.
  • 24- Wiebe, VJ, Howard, JP. Pharmacologic advances in canine and feline reproduction. Top Companion Anim Med. 2009; 24(2): 71-99.
  • 25- Erünal-Maral N, Aslan S, Fındık M, et al. Alfaprostol (Gabbrostim™) induction of abortion in queens by administration of cabergoline (Galastop™) solely or in combination with the PGF2α analogue. Theriogenology. 2004; 61(7): 1471-1475.
  • 26- Hollinshead F, Krekeler N. Pyometra in the queen: To spay or not to spay? J Feline Med Surg. 2016; 18(1): 21-33.
  • 27- England GCW, Freeman SL, Russo M. Treatment of spontaneous pyometra in 22 bitches with a combination of cabergoline and cloprostenol. Vet Rec. 2007; 160: 293-296.
  • 28- Jena B, Rao KS, Reddy KCS, et al. Comparative efficacy of various therapeutic protocols in the treatment of pyometra in bitches. Vet Med. 2013; 58(5): 271-276.
  • 29- Gobello C, De La Sota RL, Goya RG. A review of canine pseudocyesis. Reprod Domest Anim. 2001; 36(6): 283-288.
  • 30- Tsutsui T, Kirihara N, Hori T, et al. Plasma progesterone and prolactin concentrations in overtly pseudopregnant bitches: a clinical study. Theriogenology. 2007; 67(5): 1032-1038.
  • 31- Mir F, Fontfaonne A. Management of pseudopregnancy lactation refractory to medical treatment in bitches Point Veterinaire. 2013; 44(334): 6-9.
  • 32- Giesenberg S. Pseudopregnancy in the bitch. Aust Vet P. 2004; 34(4): 164-168.
  • 33- Harvey MJA, Cauvin A, Dale M, et al. Effect and mechanisms of the antiprolactin drug cabergoline on pseudopregnancy in the bitch. J Small Anim Pract. 1997; 38(8):36-339.
  • 34- Baştan A, Fındık M, Erunal N, et al. The use of cabergoline for treatment of pseudopregnancy in dogs with the purpose of suppressing lactation. Reprod Domest Anim. 1998; 33(2): 49-53.
  • 35- Sathiamoorthy T, Kulasekar K, Joseph C, et al. Clinical management of pseudopregnancy in bitches with cabergoline. Indian Vet J. 2007; 84(2): 184- 185.
  • 36- Dvojkovic N, Macesic N, Bacic G, et al. Feline fibroepithelial hyperplasia (FEH) treatment options. Kleintierpraxis. 2015; 60(5): 237-243.
  • 37- Wehrend A, Hospes R, Gruber AD. Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Vet Rec. 2001; 148(11): 346.
  • 38- MacDougalL LD. Mammary fibroadenomatous hyperplasia in a young cat attributed to treatment with megestrol acetate. Can Vet J. 2003; 44(3): 227-229.
  • 39- Concannon PW, Verstegen J. Some unique aspects of canine and feline female reproduction important in veterinary practice. In Proc.: 3rd World Congress of the World Small Anim. Vet. Assoc. 11-14 May 2005. Mexico City, Mexico.
  • 40- Uçmak M, Enginler SÖ, Gündüz MC, et al. Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline. Acta Vet Eurasia. 2011; 37(1): 69-74.
  • 41- Boutinaud M, Isaka N., Lollivier V, et al. Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off. J Dairy Sci. 2016; 99(7): 5707-5718.
  • 42- Özyurtlu N, Doğruer G, 2016. Memenin Fizyolojisi In: Kaymaz M. , Fındık M. , Rişvanlı A. , Köker A, ed.Evcil Hayvanlarda Meme Hastalıkları 1. Baskı Malatya Medipres Matbaacılık Yayıncılık Ltd. Şti. 2016: 23-35.
  • 43- Bach A, De-Prado A, Aris A. The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior. J Dairy Sci. 2015; 98(10): 7097-7101.
  • 44- Bertulat S, Isaka N, de Prado A, et al. Effect of a single injection of cabergoline at dry off on udder characteristics in high-yielding dairy cows. J Dairy Sci. 2017; 100(4): 3220-3232.
There are 42 citations in total.

Details

Primary Language English
Subjects Veterinary Surgery
Journal Section Review
Authors

Kudret Yenılmez 0000-0002-5532-0525

Nihal Eren This is me 0000-0001-8235-8978

Publication Date July 18, 2019
Published in Issue Year 2019

Cite

APA Yenılmez, K., & Eren, N. (2019). The Utilization Areas of Cabergoline in Veterinary Gynecology. Journal of Research in Veterinary Medicine, 38(1), 77-81. https://doi.org/10.30782/uluvfd.418900
AMA Yenılmez K, Eren N. The Utilization Areas of Cabergoline in Veterinary Gynecology. J Res Vet Med. July 2019;38(1):77-81. doi:10.30782/uluvfd.418900
Chicago Yenılmez, Kudret, and Nihal Eren. “The Utilization Areas of Cabergoline in Veterinary Gynecology”. Journal of Research in Veterinary Medicine 38, no. 1 (July 2019): 77-81. https://doi.org/10.30782/uluvfd.418900.
EndNote Yenılmez K, Eren N (July 1, 2019) The Utilization Areas of Cabergoline in Veterinary Gynecology. Journal of Research in Veterinary Medicine 38 1 77–81.
IEEE K. Yenılmez and N. Eren, “The Utilization Areas of Cabergoline in Veterinary Gynecology”, J Res Vet Med, vol. 38, no. 1, pp. 77–81, 2019, doi: 10.30782/uluvfd.418900.
ISNAD Yenılmez, Kudret - Eren, Nihal. “The Utilization Areas of Cabergoline in Veterinary Gynecology”. Journal of Research in Veterinary Medicine 38/1 (July 2019), 77-81. https://doi.org/10.30782/uluvfd.418900.
JAMA Yenılmez K, Eren N. The Utilization Areas of Cabergoline in Veterinary Gynecology. J Res Vet Med. 2019;38:77–81.
MLA Yenılmez, Kudret and Nihal Eren. “The Utilization Areas of Cabergoline in Veterinary Gynecology”. Journal of Research in Veterinary Medicine, vol. 38, no. 1, 2019, pp. 77-81, doi:10.30782/uluvfd.418900.
Vancouver Yenılmez K, Eren N. The Utilization Areas of Cabergoline in Veterinary Gynecology. J Res Vet Med. 2019;38(1):77-81.